KNOWLEDGE PORTAL
on innovation and access to medicines

“The AMR Action Fund is the world’s largest public-private partnership investing in the development of new antimicrobial therapeutics…We invest in companies that are developing urgently needed therapeutics for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Our aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation” (AMR Action Fund, n.d.).

“AAHI is a nonprofit biotech research institute, bringing together the best experts, technologies, and platforms to create accessible, high-quality products and solutions for harnessing the immune system to alleviate disease…For nearly three decades, the Access to Advanced Health Institute (AAHI) and its predecessor, the Infectious Disease Research Institute (IDRI), have focused on creating technologies that improve the body’s natural response to disease” (AAHI, n.d.).

Audacity Therapeutics is a Public Benefit Pharmaceutical Company whose mandate is to “contribute to a more sustainable healthcare system, develop treatments neglected or shelved by other companies, prioritize drug projects with great therapeutic potential vs profit potential, [and] run a thriving business serving the public health” (Audacity, n.d.).

“Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines…We are committed to saving and improving lives by unlocking the power of the immune system…By 2025 we aspire to be one of the largest pure play vaccine companies, improving and saving lives by excelling in R&D innovation, manufacturing and commercialization” (Bavarian Nordic, n.d.).

The BMGF’s “Global Health Division aims to reduce inequities in health by developing new tools and strategies to reduce the burden of infectious disease and the leading causes of child mortality in developing countries” (BMGF, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

“Launched in 2014, the Accelerating Medicines Partnership® (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical and life science companies, non-profit and other organizations to transform the current model for developing new diagnostics and treatments. AMP partners share a common goal of increasing the number of new diagnostics and therapies for patients and reducing the time and cost of developing them. The AMP program aims to improve understanding of therapeutically relevant biological pathways and validate information that could be relevant for the development of multiple therapeutics” (NIH.gov, n.d.).

“Aldatu Biosciences was founded in 2014 by Dr. Iain MacLeod and Dr. David Raiser with the aims of advancing infectious disease diagnostics with the PANDAA™ technology and providing easy-to-use, low-cost diagnostic tests in resource-limited areas. Based on the PANDAA™ platform, we have expanded our work to diagnostic applications for the detection of SARS-CoV-2, Lassa fever, and drug-resistant HIV variants. We strive to establish innovative technologies that improve the quality of healthcare and patient outcomes” (Aldatu Biosciences, n.d.).

“BIO Ventures for Global Health (BVGH) is a nonprofit organization based in Seattle, Washington working at the crossroads of the private and public sectors to advance research and improve health. BVGH connects people, resources, and ideas across biotechnology and pharmaceutical companies, governments, and nonprofits to solve global health issues. BVGH strategically develops and manages programs across the for-profit and non-profit sectors to accelerate research and development (R&D) for poverty-related diseases; build biomedical R&D capacity in low- and middle-income countries (LMICs); and improve cancer patient care in Africa” (BVGH, n.d.).

This initiative was selected based on its inclusion in the report “RE:ROUTE, A map of the alternative biomedical R&D landscape”, (Kiddell-Monroe, Greenberg, and Basey 2016).

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™, focused on the development of an automated insulin delivery system. Since 2015, Beta Bionics mission has been “to help improve health outcomes and the quality of life of all children and adults living with diabetes and other conditions of glycemic dysregulation” (Beta Bionics, n.d.).

DRIVe’s mission is “to help BARDA be prepared for any public health emergency by identifying and derisking the world's most promising technologies and capabilities, no matter their origin, towards the development of tomorrow's medical countermeasures”, and their vision is to “ensure the most effective life-saving medical countermeasures are developed for, available to, and used by everyone who needs them when they need them” (DRIVe, n.d.).

Bugworks is a SME headquartered in the USA with subsidiaries in India and Australia, that is “developing a novel class of broad-spectrum antibacterial agents and immunotherapies to treat patients with critical care needs in infection and cancer” and they have “discovered novel dual target acting microbial agents now in clinical trials” (Bugworks, n.d.).